This suggests potential heterogeneity in tumor response from tumor to tumor and also suggests that antibody drug conjugates targeted at SSTR2 may only lead to enriched killing of SSTR2+ cell subpopulations. This evidence concerns the gene SSTR2 and neoplasm.